Plain-English translation of NCT04616131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study looks at cancer DNA that circulates in your bloodstream—a marker that may help doctors understand how your pancreatic cancer is responding to chemotherapy. By tracking this blood marker before, during, and after your treatment, researchers hope to learn whether it can predict treatment success and guide doctors in making better decisions about your care.
Pancreatic cancer is difficult to treat, and doctors currently have limited tools to quickly assess whether chemotherapy is working. This study aims to determine whether blood tests can provide an earlier, clearer picture of how your cancer is responding to treatment, which could help doctors adjust your plan sooner and improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
You will have blood samples drawn at several time points during and after your chemotherapy treatment. The research team will analyze your blood for cancer DNA markers to see how your cancer responds to therapy. This is an observational study, meaning researchers are monitoring and collecting information rather than giving you a new experimental drug—your regular cancer treatment plan continues as planned by your doctor.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Sponsor
Northwestern University
Enrollment target
~500 participants
Started
October 2020
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Coordinator
Northwestern Medicine Warrenville
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.